NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.60
+2.63%0
Insider buys (3m)
5
Insider sells (3m)
-$340.0K
Net value (3m)
+44.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 600 | $36 |
| Jul 7, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 4,200 | $36 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 739 | $34 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 2,531 | $35 |
| Jul 2, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 1,530 | $35 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 7,700 | $43 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 15,400 | $32 |
| Jun 16, 2026 | Woods Keith · director | A-Award | 12,050 | $20 |
| May 8, 2026 | Cvijic Christine Mikail · director, officer: President and CFO | Sale | 4,800 | $30 |
| May 7, 2026 | Shafer Christina · officer: Chief Commercial Officer | A-Award | 120,000 | $29 |
| Mar 30, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 2,558 | $22 |
| Mar 30, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | Sale | 3,352 | $22 |
| Mar 30, 2026 | Jordan Julie · officer: Chief Medical Officer | Sale | 828 | $22 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 1,395 | $21 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 263 | $22 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 3,991 | $20 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 2,658 | $21 |
| Mar 17, 2026 | Cobb Stuart · officer: Chief Scientific Officer | Sale | 148 | $22 |
| Mar 17, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 2,387 | $20 |
| Mar 3, 2026 | Cvijic Christine Mikail · officer: President and CFO | Sale | 4,800 | $25 |
| Feb 24, 2026 | BAFFI ROBERT · director | A-Award | 12,050 | $18 |
| Feb 24, 2026 | Cobb Stuart · officer: Chief Scientific Officer | A-Award | 16,500 | $0.00 |
| Feb 24, 2026 | Jordan Julie · officer: Chief Medical Officer | A-Award | 4,900 | $0.00 |
| Feb 24, 2026 | Jordan Julie · officer: Chief Medical Officer | A-Award | 29,600 | $18 |
| Feb 24, 2026 | Cvijic Christine Mikail · officer: President and CFO | A-Award | 22,000 | $0.00 |
| Feb 24, 2026 | Cvijic Christine Mikail · officer: President and CFO | A-Award | 131,900 | $18 |
| Feb 24, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | A-Award | 25,900 | $0.00 |
| Feb 24, 2026 | McMinn Rachel · director, officer: Chief Executive Officer | A-Award | 155,100 | $18 |
| Feb 24, 2026 | Woods Keith · director | A-Award | 12,050 | $18 |
| Feb 24, 2026 | Freedland Cory S. · director | A-Award | 12,050 | $18 |
Institutional positioning
13F filings over the trailing two quarters
New 19Increased 47Reduced 16Sold out 95
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | Unchanged | 1,717,127 | May 15, 2026 |
| REDMILE GROUP, LLC | Unchanged | 1,459,599 | May 15, 2026 |
| CASDIN CAPITAL, LLC | Increased | 1,420,361 | May 15, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 1,362,456 | May 15, 2026 |
| ECOR1 CAPITAL, LLC | Unchanged | 1,271,342 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 1,005,070 | May 13, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 991,691 | May 15, 2026 |
| Trails Edge Capital Partners, LP | Reduced | 782,787 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 718,389 | May 15, 2026 |
| TORONTO DOMINION BANK | Unchanged | 681,337 | May 15, 2026 |
| JENNISON ASSOCIATES LLC | Reduced | 527,685 | May 6, 2026 |
| ARROWMARK COLORADO HOLDINGS LLC | Reduced | 524,796 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 514,727 | May 15, 2026 |
| GREAT POINT PARTNERS LLC | Increased | 500,000 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 435,682 | Sep 2, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 7, 2026